Summary & Overview
HCPCS C9463: Aprepitant Injection, 1 mg
HCPCS Level II code C9463 represents a 1 mg injectable formulation of aprepitant, an antiemetic used primarily to prevent chemotherapy-induced nausea and vomiting. As an HCPCS Level II code for a specific drug formulation administered by injection, C9463 matters nationally for clinicians, infusion centers, hospitals, and payers managing oncology supportive care and medication benefit carve-outs. Accurate use of this code affects claims processing, pharmacy-billing workflows, and reporting of delivered therapy.
This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the clinical context for injectable aprepitant, and the typical sites of service where the drug is administered. The publication outlines what stakeholders typically examine for this code: billing and coding practice, payer coverage considerations, and how the code integrates into infusion and oncology service lines.
The report provides practical benchmarks and policy-relevant observations such as common billing scenarios involving injectable antiemetics, areas where coding mismatches commonly occur, and implications for reimbursement workflows. It also highlights where additional data is needed and notes when input fields were not provided. The content is intended for billing managers, clinicians involved in oncology supportive care, revenue cycle staff, and policy analysts focused on drug administration billing.
Billing Code Overview
HCPCS Level II code C9463 denotes Injection, aprepitant, 1 mg. This billing code represents a parenteral formulation of aprepitant, an antiemetic agent used to prevent chemotherapy-induced nausea and vomiting and for other clinically relevant indications where an intravenous or injectable dose is required. The service type is an injection/infusion medication administration, and the typical site of service is an outpatient infusion center, hospital outpatient department, or clinic where injectable antiemetic therapy is administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving chemotherapy with a high emetogenic potential (for example, a cisplatin-based regimen) who requires antiemetic prophylaxis. The medication C9463 (injection, aprepitant, 1 mg) is administered as part of an antiemetic regimen to prevent acute and delayed chemotherapy-induced nausea and vomiting. The workflow: patient checks in to an outpatient infusion center or hospital outpatient department; nursing verifies chemotherapy order and antiemetic protocol; pharmacist compounds the aprepitant injection per order; medication is administered intravenously or via IV push/infusion immediately prior to or with chemotherapy according to institutional protocol; nursing documents lot number, dose, route, time, and any immediate adverse reactions in the infusion record; billing staff reports HCPCS Level II code C9463 (units reflecting mg administered) with any applicable modifiers and links to the chemotherapy administration encounter and the primary oncology diagnosis on the claim.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when a distinct E/M is performed on the same day as administration and documentation supports a separate service |